INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

Innovative Pharmaceutical Biotech Limited

Equities

399 BMG4783W1073

Industrial Machinery & Equipment

Market Closed - Hong Kong S.E. Other stock markets 04:08:10 2024-05-21 am EDT			5-day change	1st Jan Change
0.195 ^HKD	0.00%		0.00%	-10.96%

2023	Innovative Pharmaceutical Biotech Returns to Fiscal H1 Attributable Profit	MT
2023	Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Half Year Ended September 30, 2023	CI

Innovative Pharmaceutical Biotech Limited Announces Retirement of Huang He as an Executive Director

August 06, 2020 at 10:53 am EDT

Innovative Pharmaceutical Biotech Limited announced that on 5 August 2020, the Company has received a written notice from Ms. Huang He. Ms. Huang informed the Board that she will retire as an executive Director with effect from the conclusion of the AGM to be held on August 31, 2020 due to her intention to concentrate on her own business engagement.

Latest news about Innovative Pharmaceutical Biotech Limited

Innovative Pharmaceutical Biotech Returns to Fiscal H1 Attributable Profit	Nov. 30	MT
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 29	CI
Innovative Pharmaceutical Biotech to Return to Profit in Fiscal H1	Nov. 28	MT
Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023	Nov. 27	CI
Innovative Pharmaceutical Biotech Limited Announces Change of Address of Principal Place of Business in Hong Kong	Nov. 07	CI
Innovative Pharmaceutical Eyes Majority Stake in US Neurotechnology Firm	23-09-05	MT
Innovative Pharmaceutical Biotech Limited entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.	23-09-03	CI
Innovative Pharmaceutical Plans HK$55.5 Million Bond Issue	23-07-28	MT
Innovative Pharmaceutical to Raise HK$58 Million From Deal with US Firm Genuine Marketing	23-07-27	MT
Innovative Pharmaceutical Biotech Limited announced that it expects to receive HKD 55.5 million in funding	23-07-26	CI
Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director	23-07-04	CI
Innovative Pharmaceutical Biotech Incurs Loss in Fiscal Year 2023	23-06-29	MT
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-29	CI
Innovative Pharmaceutical Biotech Mulls Over Capital Injection in Technical Services Company	23-01-20	MT
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-29	CI
Innovative Pharmaceutical Biotech Forecasts Swing to Loss in April-September Period	22-11-24	MT
Innovative Pharmaceutical Biotech Limited Provides Group Earnings Guidance for the Six Months Ending 30 September 2022	22-11-24	CI
Innovative Pharmaceutical Biotech Limited Auditor Raises 'Going Concern' Doubt	22-07-28	CI
Innovative Pharmaceutical Biotech Limited Announces Delay in Publication of Audited Annual Results for the Year Ended 31 March 2022	22-06-29	CI
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-29	CI
Innovative Pharmaceutical Biotech Swings to Profit on Noncash Item Credit in Fiscal H1	21-11-30	MT
Innovative Pharmaceutical Biotech Limited Reports Earnings Results for the Half Year Ended September 30, 2021	21-11-29	CI
Innovative Pharmaceutical to Swing to Fiscal H1 Profit	21-11-26	MT
Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending September 30, 2021	21-11-25	CI
Singapore's Temasek portfolio surges to record after market rally	21-07-13	RE

Chart Innovative Pharmaceutical Biotech Limited

Duration

Period

Chart Innovative Pharmaceutical Biotech Limited

More charts

Company Profile

Innovative Pharmaceutical Biotech Limited is a Hong Kong-based investment holding company principally engaged in pharmaceuticals and biotechnology businesses. The Company operates through five segments. Genetic Testing Services segment is engaged in the provision of genetic testing services in the Peopleâs Republic of China (PRC) and Hong Kong. Bio-Industrial Products segment is engaged in the distribution of bio-industrial products in the PRC. Beauty Equipment and Products segment is engaged in the trading of beauty equipment and products in Hong Kong. Securities Investment segment is engaged in securities investment in Hong Kong and outside Hong Kong. Research and Development segment is engaged in the research, development and commercialization of the oral insulin products.

Sector

Industrial Machinery & Equipment

Calendar

2024-06-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Industrial Machinery & Equipment Wholesale

	1st Jan change	Capi.
INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED	-10.96%	43.09M
W.W. GRAINGER, INC.	+14.99%	46.78B
FASTENAL COMPANY	+2.50%	38.17B
APPLIED INDUSTRIAL TECHNOLOGIES, INC.	+15.74%	7.76B
DIPLOMA PLC	+17.36%	7.17B
MSC INDUSTRIAL DIRECT CO., INC.	-9.29%	5.21B
DISTRIBUTION SOLUTIONS GROUP, INC.	+14.77%	1.72B
DNOW INC.	+25.71%	1.49B
BUFAB AB	-2.48%	1.35B
MRC GLOBAL INC.	+24.57%	1.16B

Industrial Machinery & Equipment Wholesale